...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
Reply New Message
Back To Forum List View
Icon president Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
5
BearDownAZ
Jun 21, 2022 08:03AM
Icon president Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
5
Nextblockbuster
Jun 21, 2022 09:16AM

I don't expect anything until (at least) the Phase II studies are done.

2 Recommendations
Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

narmac
Jun 22, 2022 07:19AM
Icon president Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
4
Nextblockbuster
Jun 22, 2022 10:40AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply